Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25337054 | 1.00 | MEN1 (0.34) | MEN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL30405771 | 1.00 | MEN1 (0.34) | MEN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL30405349 | 1.00 | MEN1 (0.34) | MEN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL30405848 | 0.96 | MEN1 (0.33) | MEN1 | |
| SCHEMBL30405842 | 0.96 | MEN1 (0.33) | MEN1 | |
| SCHEMBL31578956 | 0.92 | KDM4E (0.36) | MEN1KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL25726812 | 0.92 | KDM4E (0.36) | MEN1KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL25726854 | 0.91 | PRKCQ (0.32) | ALDH1A1 | |
| SCHEMBL30404914 | 0.90 | IRAK4 (0.32) | MEN1 | |
| SCHEMBL25436592 | 0.89 | KDM4E (0.34) | MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY INC (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | MEN1, ABCB1, ABCC1 | MEN1 1/4885KDM4E 3774/4885ALDH1A1 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.